{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:40:27Z","timestamp":1792896027854,"version":"4.5.0"},"reference-count":272,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41568-025-00857-0","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T09:17:12Z","timestamp":1755767832000},"page":"965-985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeting the roots of myeloid malignancies with T cell receptors"],"prefix":"10.1038","volume":"25","author":[{"given":"Zsofia","family":"Foldvari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8864-4147","authenticated-orcid":false,"given":"Margs S.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksei","family":"Titov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1362-3659","authenticated-orcid":false,"given":"Sten Eirik W.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-3100","authenticated-orcid":false,"given":"Johanna","family":"Olweus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"857_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber, D. A. et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140, 1200\u20131228 (2022).","journal-title":"Blood"},{"key":"857_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.trecan.2023.05.004","volume":"9","author":"K Takahashi","year":"2023","unstructured":"Takahashi, K. & Tanaka, T. Clonal evolution and hierarchy in myeloid malignancies. Trends Cancer 9, 707\u2013715 (2023).","journal-title":"Trends Cancer"},{"key":"857_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"857_CR4","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","volume":"37","author":"C Rausch","year":"2023","unstructured":"Rausch, C. et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia 37, 1234\u20131244 (2023).","journal-title":"Leukemia"},{"key":"857_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJM195709122571102","volume":"257","author":"ED Thomas","year":"1957","unstructured":"Thomas, E. D., Lochte, H. L., Lu, W. C. & Ferrebee, J. W. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N. Engl. J. Med. 257, 491\u2013496 (1957).","journal-title":"N. Engl. J. Med."},{"key":"857_CR6","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","volume":"133","author":"U Platzbecker","year":"2019","unstructured":"Platzbecker, U. Treatment of MDS. Blood 133, 1096\u20131107 (2019).","journal-title":"Blood"},{"key":"857_CR7","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3390\/cells9061559","volume":"9","author":"LM Braun","year":"2020","unstructured":"Braun, L. M. & Zeiser, R. Immunotherapy in myeloproliferative diseases. Cells 9, 1559 (2020).","journal-title":"Cells"},{"key":"857_CR8","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1182\/blood.2023023476","volume":"143","author":"F Onida","year":"2024","unstructured":"Onida, F. et al. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee. Blood 143, 2227\u20132244 (2024).","journal-title":"Blood"},{"key":"857_CR9","doi-asserted-by":"publisher","DOI":"10.1017\/pcm.2023.9","volume":"1","author":"S Leak","year":"2023","unstructured":"Leak, S., Horne, G. A. & Copland, M. Targeting BCR\u2013ABL1-positive leukaemias: a review article. Camb. Prism. Precis. Med. 1, e21 (2023).","journal-title":"Camb. Prism. Precis. Med."},{"key":"857_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3389\/fonc.2019.01217","volume":"9","author":"C Sweeney","year":"2019","unstructured":"Sweeney, C. & Vyas, P. The graft-versus-leukemia effect in AML. Front. Oncol. 9, 1217 (2019).","journal-title":"Front. Oncol."},{"key":"857_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","volume":"9","author":"F Malard","year":"2023","unstructured":"Malard, F., Holler, E., Sandmaier, B. M., Huang, H. & Mohty, M. Acute graft-versus-host disease. Nat. Rev. Dis. Prim. 9, 27 (2023).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"857_CR12","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","volume":"276","author":"C Bonini","year":"1997","unstructured":"Bonini, C. et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719\u20131724 (1997).","journal-title":"Science"},{"key":"857_CR13","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673\u20131683 (2011).","journal-title":"N. Engl. J. Med."},{"key":"857_CR14","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","volume":"300","author":"PL Weiden","year":"1979","unstructured":"Weiden, P. L. et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300, 1068\u20131073 (1979).","journal-title":"N. Engl. J. Med."},{"key":"857_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz, M. M. et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555\u2013562 (1990).","journal-title":"Blood"},{"key":"857_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.7326\/0003-4819-120-8-199404150-00004","volume":"120","author":"RP Gale","year":"1994","unstructured":"Gale, R. P. et al. Identical-twin bone marrow transplants for leukemia. Ann. Intern. Med. 120, 646\u2013652 (1994).","journal-title":"Ann. Intern. Med."},{"key":"857_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/JCO.2007.11.1641","volume":"26","author":"D Valcarcel","year":"2008","unstructured":"Valcarcel, D. et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J. Clin. Oncol. 26, 577\u2013584 (2008).","journal-title":"J. Clin. Oncol."},{"key":"857_CR18","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1038\/leu.2012.135","volume":"26","author":"F Baron","year":"2012","unstructured":"Baron, F. et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 26, 2462\u20132468 (2012).","journal-title":"Leukemia"},{"key":"857_CR19","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1182\/blood.V78.8.2120.2120","volume":"78","author":"AM Marmont","year":"1991","unstructured":"Marmont, A. M. et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78, 2120\u20132130 (1991).","journal-title":"Blood"},{"key":"857_CR20","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","volume":"76","author":"HJ Kolb","year":"1990","unstructured":"Kolb, H. J. et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462\u20132465 (1990).","journal-title":"Blood"},{"key":"857_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2023.101484","volume":"36","author":"NA Shah","year":"2023","unstructured":"Shah, N. A. Donor lymphocyte infusion in acute myeloid leukemia. Best. Pract. Res. Clin. Haematol. 36, 101484 (2023).","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"857_CR22","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","volume":"133","author":"R Zeiser","year":"2019","unstructured":"Zeiser, R. & Vago, L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood 133, 1290\u20131297 (2019).","journal-title":"Blood"},{"key":"857_CR23","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMoa0811036","volume":"361","author":"L Vago","year":"2009","unstructured":"Vago, L. et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N. Engl. J. Med. 361, 478\u2013488 (2009).","journal-title":"N. Engl. J. Med."},{"key":"857_CR24","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher, M. J. et al. Immune escape of relapsed AML cells after allogeneic transplantation. N. Engl. J. Med. 379, 2330\u20132341 (2018).","journal-title":"N. Engl. J. Med."},{"key":"857_CR25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"C Toffalori","year":"2019","unstructured":"Toffalori, C. et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat. Med. 25, 603\u2013611 (2019).","journal-title":"Nat. Med."},{"key":"857_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.634435","volume":"12","author":"N Kohler","year":"2021","unstructured":"Kohler, N., Ruess, D. A., Kesselring, R. & Zeiser, R. The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation. Front. Immunol. 12, 634435 (2021).","journal-title":"Front. Immunol."},{"key":"857_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41571-020-0356-4","volume":"17","author":"BR Blazar","year":"2020","unstructured":"Blazar, B. R., Hill, G. R. & Murphy, W. J. Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. Nat. Rev. Clin. Oncol. 17, 475\u2013492 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"857_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"857_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"857_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"857_CR31","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","volume":"200","author":"DT Harris","year":"2018","unstructured":"Harris, D. T. et al. Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains. J. Immunol. 200, 1088\u20131100 (2018).","journal-title":"J. Immunol."},{"key":"857_CR32","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41590-020-0719-0","volume":"21","author":"V Gudipati","year":"2020","unstructured":"Gudipati, V. et al. Inefficient CAR-proximal signaling blunts antigen sensitivity. Nat. Immunol. 21, 848\u2013856 (2020).","journal-title":"Nat. Immunol."},{"key":"857_CR33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2216352120","volume":"120","author":"J Burton","year":"2023","unstructured":"Burton, J. et al. Inefficient exploitation of accessory receptors reduces the sensitivity of chimeric antigen receptors. Proc. Natl Acad. Sci. USA 120, e2216352120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl5282","volume":"376","author":"X Zhao","year":"2022","unstructured":"Zhao, X. et al. Tuning T cell receptor sensitivity through catch bond engineering. Science 376, eabl5282 (2022).","journal-title":"Science"},{"key":"857_CR35","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo, S. P. et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 403, 1460\u20131471 (2024).","journal-title":"Lancet"},{"key":"857_CR36","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","volume":"358","author":"NN Hunder","year":"2008","unstructured":"Hunder, N. N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698\u20132703 (2008).","journal-title":"N. Engl. J. Med."},{"key":"857_CR37","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641\u2013645 (2014).","journal-title":"Science"},{"key":"857_CR38","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","volume":"35","author":"YC Lu","year":"2017","unstructured":"Lu, Y. C. et al. Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. J. Clin. Oncol. 35, 3322\u20133329 (2017).","journal-title":"J. Clin. Oncol."},{"key":"857_CR39","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","volume":"57","author":"JA Snowden","year":"2022","unstructured":"Snowden, J. A. et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transpl. 57, 1217\u20131239 (2022).","journal-title":"Bone Marrow Transpl."},{"key":"857_CR40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.stem.2012.01.006","volume":"10","author":"S Doulatov","year":"2012","unstructured":"Doulatov, S., Notta, F., Laurenti, E. & Dick, J. E. Hematopoiesis: a human perspective. Cell Stem Cell 10, 120\u2013136 (2012).","journal-title":"Cell Stem Cell"},{"key":"857_CR41","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nature25022","volume":"553","author":"E Laurenti","year":"2018","unstructured":"Laurenti, E. & Gottgens, B. From haematopoietic stem cells to complex differentiation landscapes. Nature 553, 418\u2013426 (2018).","journal-title":"Nature"},{"key":"857_CR42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1182\/blood.2022017864","volume":"142","author":"M Jassinskaja","year":"2023","unstructured":"Jassinskaja, M., Gonka, M. & Kent, D. G. Resolving the hematopoietic stem cell state by linking functional and molecular assays. Blood 142, 543\u2013552 (2023).","journal-title":"Blood"},{"key":"857_CR43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","volume":"14","author":"A Kreso","year":"2014","unstructured":"Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell Stem Cell 14, 275\u2013291 (2014).","journal-title":"Cell Stem Cell"},{"key":"857_CR44","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645\u2013648 (1994).","journal-title":"Nature"},{"key":"857_CR45","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730\u2013737 (1997).","journal-title":"Nat. Med."},{"key":"857_CR46","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ccr.2014.03.036","volume":"25","author":"PS Woll","year":"2014","unstructured":"Woll, P. S. et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 25, 794\u2013808 (2014).","journal-title":"Cancer Cell"},{"key":"857_CR47","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/ng.3646","volume":"48","author":"MR Corces","year":"2016","unstructured":"Corces, M. R. et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat. Genet. 48, 1193\u20131203 (2016).","journal-title":"Nat. Genet."},{"key":"857_CR48","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","volume":"23","author":"A Giustacchini","year":"2017","unstructured":"Giustacchini, A. et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat. Med. 23, 692\u2013702 (2017).","journal-title":"Nat. Med."},{"key":"857_CR49","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","volume":"73","author":"A Rodriguez-Meira","year":"2019","unstructured":"Rodriguez-Meira, A. et al. Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing. Mol. Cell 73, 1292\u20131305.e8 (2019).","journal-title":"Mol. Cell"},{"key":"857_CR50","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.immuni.2023.09.002","volume":"56","author":"M M\u00fcller","year":"2023","unstructured":"M\u00fcller, M. et al. Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction. Immunity 56, 2650\u20132663.e6 (2023).","journal-title":"Immunity"},{"key":"857_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41587-019-0322-9","volume":"38","author":"S Sarkizova","year":"2020","unstructured":"Sarkizova, S. et al. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat. Biotechnol. 38, 199\u2013209 (2020).","journal-title":"Nat. Biotechnol."},{"key":"857_CR52","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s41592-020-0867-z","volume":"18","author":"AV Joglekar","year":"2021","unstructured":"Joglekar, A. V. & Li, G. T cell antigen discovery. Nat. Methods 18, 873\u2013880 (2021).","journal-title":"Nat. Methods"},{"key":"857_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658372","volume":"12","author":"KAK Finton","year":"2021","unstructured":"Finton, K. A. K. et al. ARTEMIS: a novel mass-spec platform for HLA-restricted self and disease-associated peptide discovery. Front. Immunol. 12, 658372 (2021).","journal-title":"Front. Immunol."},{"key":"857_CR54","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s43018-023-00548-5","volume":"4","author":"AI Kraemer","year":"2023","unstructured":"Kraemer, A. I. et al. The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer. Nat. Cancer 4, 608\u2013628 (2023).","journal-title":"Nat. Cancer"},{"key":"857_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02420-y","author":"F Huber","year":"2024","unstructured":"Huber, F. et al. A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02420-y (2024).","journal-title":"Nat. Biotechnol."},{"key":"857_CR56","doi-asserted-by":"publisher","first-page":"111995","DOI":"10.1016\/j.celrep.2023.111995","volume":"42","author":"S Meyer","year":"2023","unstructured":"Meyer, S. et al. Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants. Cell Rep. 42, 111995 (2023).","journal-title":"Cell Rep."},{"key":"857_CR57","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.cell.2014.03.047","volume":"157","author":"ME Birnbaum","year":"2014","unstructured":"Birnbaum, M. E. et al. Deconstructing the peptide\u2013MHC specificity of T cell recognition. Cell 157, 1073\u20131087 (2014).","journal-title":"Cell"},{"key":"857_CR58","doi-asserted-by":"publisher","unstructured":"Gaglione, S. A. et al. Scalable TCR synthesis and screening enables antigen reactivity mapping in vitiligo. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.04.24.649726 (2025).","DOI":"10.1101\/2025.04.24.649726"},{"key":"857_CR59","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2019.07.009","volume":"178","author":"T Kula","year":"2019","unstructured":"Kula, T. et al. T-Scan: a genome-wide method for the systematic discovery of T cell epitopes. Cell 178, 1016\u20131028.e13 (2019).","journal-title":"Cell"},{"key":"857_CR60","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1016\/j.cell.2023.10.024","volume":"186","author":"MH Dezfulian","year":"2023","unstructured":"Dezfulian, M. H. et al. TScan-II: a genome-scale platform for the de novo identification of CD4+ T cell epitopes. Cell 186, 5569\u20135586.e21 (2023).","journal-title":"Cell"},{"key":"857_CR61","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41587-024-02210-6","volume":"43","author":"Z Moravec","year":"2024","unstructured":"Moravec, Z. et al. Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening. Nat. Biotechnol. 43, 214\u2013222 (2024).","journal-title":"Nat. Biotechnol."},{"key":"857_CR62","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1126\/science.aaf2288","volume":"352","author":"E Str\u00f8nen","year":"2016","unstructured":"Str\u00f8nen, E. et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337\u20131341 (2016).","journal-title":"Science"},{"key":"857_CR63","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1038\/s41596-019-0170-6","volume":"14","author":"M Ali","year":"2019","unstructured":"Ali, M. et al. Induction of neoantigen-reactive T cells from healthy donors. Nat. Protoc. 14, 1926\u20131943 (2019).","journal-title":"Nat. Protoc."},{"key":"857_CR64","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319, 1676\u20131680 (1988).","journal-title":"N. Engl. J. Med."},{"key":"857_CR65","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1073\/pnas.0830997100","volume":"100","author":"FS Hodi","year":"2003","unstructured":"Hodi, F. S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100, 4712\u20134717 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR66","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"857_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.882531","volume":"12","author":"M Gomez-Llobell","year":"2022","unstructured":"Gomez-Llobell, M., Peleteiro Raindo, A., Climent Medina, J., Gomez Centurion, I. & Mosquera Orgueira, A. Immune checkpoint inhibitors in acute myeloid leukemia: a meta-analysis. Front. Oncol. 12, 882531 (2022).","journal-title":"Front. Oncol."},{"key":"857_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.637420","volume":"11","author":"J Handlos Grauslund","year":"2021","unstructured":"Handlos Grauslund, J. et al. Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic myeloproliferative neoplasms. Front. Oncol. 11, 637420 (2021).","journal-title":"Front. Oncol."},{"key":"857_CR69","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fimmu.2015.00036","volume":"6","author":"A Di Stasi","year":"2015","unstructured":"Di Stasi, A., Jimenez, A. M., Minagawa, K., Al-Obaidi, M. & Rezvani, K. Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front. Immunol. 6, 36 (2015).","journal-title":"Front. Immunol."},{"key":"857_CR70","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126\u2013129 (2006).","journal-title":"Science"},{"key":"857_CR71","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196\u20131206 (2021).","journal-title":"N. Engl. J. Med."},{"key":"857_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1027548","volume":"12","author":"HP Gerber","year":"2022","unstructured":"Gerber, H. P. & Presta, L. G. TCR mimic compounds for pHLA targeting with high potency modalities in oncology. Front. Oncol. 12, 1027548 (2022).","journal-title":"Front. Oncol."},{"key":"857_CR73","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","volume":"22","author":"CA Klebanoff","year":"2023","unstructured":"Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A. & Ribas, A. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nat. Rev. Drug. Discov. 22, 996\u20131017 (2023).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"857_CR74","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.4049\/jimmunol.157.5.1823","volume":"157","author":"JW Yewdell","year":"1996","unstructured":"Yewdell, J. W., Ant\u00f3n, L. C. & Bennink, J. R. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J. Immunol. 157, 1823\u20131826 (1996).","journal-title":"J. Immunol."},{"key":"857_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2022.100230","volume":"21","author":"JW Yewdell","year":"2022","unstructured":"Yewdell, J. W. MHC class I immunopeptidome: past, present, and future. Mol. Cell Proteom. 21, 100230 (2022).","journal-title":"Mol. Cell Proteom."},{"key":"857_CR76","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1074\/mcp.M114.042812","volume":"14","author":"M Bassani-Sternberg","year":"2015","unstructured":"Bassani-Sternberg, M., Pletscher-Frankild, S., Jensen, L. J. & Mann, M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol. Cell Proteom. 14, 658\u2013673 (2015).","journal-title":"Mol. Cell Proteom."},{"key":"857_CR77","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.4049\/jimmunol.153.12.5586","volume":"153","author":"A Sette","year":"1994","unstructured":"Sette, A. et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153, 5586\u20135592 (1994).","journal-title":"J. Immunol."},{"key":"857_CR78","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.4049\/jimmunol.156.9.3308","volume":"156","author":"SH van der Burg","year":"1996","unstructured":"van der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M. & Melief, C. J. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC\u2013peptide complex stability. J. Immunol. 156, 3308\u20133314 (1996).","journal-title":"J. Immunol."},{"key":"857_CR79","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/eji.201141774","volume":"42","author":"M Harndahl","year":"2012","unstructured":"Harndahl, M. et al. Peptide\u2013MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur. J. Immunol. 42, 1405\u20131416 (2012).","journal-title":"Eur. J. Immunol."},{"key":"857_CR80","first-page":"789","volume":"14","author":"H Sugiyama","year":"2000","unstructured":"Sugiyama, H. Cancer immunotherapy targeting WT1 protein. Biotherapy 14, 789\u2013795 (2000).","journal-title":"Biotherapy"},{"key":"857_CR81","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1182\/blood-2002-06-1831","volume":"101","author":"H Ogawa","year":"2003","unstructured":"Ogawa, H. et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101, 1698\u20131704 (2003).","journal-title":"Blood"},{"key":"857_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.994366","volume":"12","author":"P Chiusolo","year":"2022","unstructured":"Chiusolo, P. et al. Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients. Front. Oncol. 12, 994366 (2022).","journal-title":"Front. Oncol."},{"key":"857_CR83","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/leu.2010.283","volume":"25","author":"T Lange","year":"2011","unstructured":"Lange, T. et al. Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 25, 498\u2013505 (2011).","journal-title":"Leukemia"},{"key":"857_CR84","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","volume":"130","author":"I Tawara","year":"2017","unstructured":"Tawara, I. et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood 130, 1985\u20131994 (2017).","journal-title":"Blood"},{"key":"857_CR85","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","volume":"25","author":"AG Chapuis","year":"2019","unstructured":"Chapuis, A. G. et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat. Med. 25, 1064\u20131072 (2019).","journal-title":"Nat. Med."},{"key":"857_CR86","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2019-128044","volume":"134","author":"EC Morris","year":"2019","unstructured":"Morris, E. C. et al. A phase I study evaluating the safety and persistence of allorestricted WT1-TCR gene modified autologous T cells in patients with high-risk myeloid malignancies unsuitable for allogeneic stem cell transplantation. Blood 134, 1367 (2019).","journal-title":"Blood"},{"key":"857_CR87","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02770820 (2021)."},{"key":"857_CR88","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05066165 (2023)."},{"key":"857_CR89","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/CJI.0000000000000116","volume":"39","author":"A Jaigirdar","year":"2016","unstructured":"Jaigirdar, A., Rosenberg, S. A. & Parkhurst, M. A high-avidity WT1-reactive T-cell receptor mediates recognition of peptide and processed antigen but not naturally occurring WT1-positive tumor cells. J. Immunother. 39, 105\u2013116 (2016).","journal-title":"J. Immunother."},{"key":"857_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01907-7","volume":"22","author":"N Tubio-Santamaria","year":"2023","unstructured":"Tubio-Santamaria, N. et al. Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. Mol. Cancer 22, 196 (2023).","journal-title":"Mol. Cancer"},{"key":"857_CR91","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg8070","volume":"14","author":"MC Lahman","year":"2022","unstructured":"Lahman, M. C. et al. Targeting an alternate Wilms\u2019 tumor antigen 1 peptide bypasses immunoproteasome dependency. Sci. Transl. Med. 14, eabg8070 (2022).","journal-title":"Sci. Transl. Med."},{"key":"857_CR92","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg8027","volume":"14","author":"E Ruggiero","year":"2022","unstructured":"Ruggiero, E. et al. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci. Transl. Med. 14, eabg8027 (2022).","journal-title":"Sci. Transl. Med."},{"key":"857_CR93","doi-asserted-by":"publisher","first-page":"5492","DOI":"10.1182\/blood-2011-07-365890","volume":"119","author":"S Ochsenreither","year":"2012","unstructured":"Ochsenreither, S. et al. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood 119, 5492\u20135501 (2012).","journal-title":"Blood"},{"key":"857_CR94","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917\u2013924 (2011).","journal-title":"J. Clin. Oncol."},{"key":"857_CR95","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133\u2013151 (2013).","journal-title":"J. Immunother."},{"key":"857_CR96","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019\u20131027 (2015).","journal-title":"Clin. Cancer Res."},{"key":"857_CR97","first-page":"2","volume":"9","author":"M Wermke","year":"2021","unstructured":"Wermke, M. et al. 959 safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses \u2014 clinical update on the ACTengine\u00ae IMA203 trial. J. Immunother. Cancer 9, 2 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"857_CR98","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong, D. S. et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat. Med. 29, 104\u2013114 (2023).","journal-title":"Nat. Med."},{"key":"857_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.624742","volume":"11","author":"KK Wong","year":"2021","unstructured":"Wong, K. K., Hassan, R. & Yaacob, N. S. Hypomethylating agents and immunotherapy: therapeutic synergism in acute myeloid leukemia and myelodysplastic syndromes. Front. Oncol. 11, 624742 (2021).","journal-title":"Front. Oncol."},{"key":"857_CR100","first-page":"234","volume":"58","author":"S Thomas","year":"2023","unstructured":"Thomas, S. et al. First-in-human study of MDG1011, a TCR-T cell therapy directed against HLA-A*02:01-restricted PRAME, for high-risk myeloid and lymphoid neoplasms. Bone Marrow Transplant. 58, 234\u2013234 (2023).","journal-title":"Bone Marrow Transplant."},{"key":"857_CR101","doi-asserted-by":"publisher","first-page":"9167","DOI":"10.1158\/0008-5472.CAN-04-1442","volume":"64","author":"L Sigalotti","year":"2004","unstructured":"Sigalotti, L. et al. Intratumor heterogeneity of cancer\/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2\u2032-deoxycytidine. Cancer Res. 64, 9167\u20139171 (2004).","journal-title":"Cancer Res."},{"key":"857_CR102","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1158\/1078-0432.CCR-07-5279","volume":"14","author":"A Woloszynska-Read","year":"2008","unstructured":"Woloszynska-Read, A., Mhawech-Fauceglia, P., Yu, J., Odunsi, K. & Karpf, A. R. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin. Cancer Res. 14, 3283\u20133290 (2008).","journal-title":"Clin. Cancer Res."},{"key":"857_CR103","doi-asserted-by":"publisher","first-page":"8954","DOI":"10.1158\/0008-5472.CAN-07-6088","volume":"68","author":"S Yegnasubramanian","year":"2008","unstructured":"Yegnasubramanian, S. et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 68, 8954\u20138967 (2008).","journal-title":"Cancer Res."},{"key":"857_CR104","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.2147\/OTT.S240979","volume":"13","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. Both methylation and copy number variation participated in the varied expression of PRAME in multiple myeloma. Onco Targets Ther. 13, 7545\u20137553 (2020).","journal-title":"Onco Targets Ther."},{"key":"857_CR105","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4049\/jimmunol.1002612","volume":"188","author":"IJ Huijbers","year":"2012","unstructured":"Huijbers, I. J. et al. Minimal tolerance to a tumor antigen encoded by a cancer-germline gene. J. Immunol. 188, 111\u2013121 (2012).","journal-title":"J. Immunol."},{"key":"857_CR106","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863\u2013871 (2013).","journal-title":"Blood"},{"key":"857_CR107","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A. & June, C. H. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707\u2013715 (2023).","journal-title":"Nature"},{"key":"857_CR108","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/leu.2010.186","volume":"24","author":"IW Abrahamsen","year":"2010","unstructured":"Abrahamsen, I. W. et al. Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia 24, 1901\u20131909 (2010).","journal-title":"Leukemia"},{"key":"857_CR109","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1073\/pnas.1306549111","volume":"111","author":"S Kumari","year":"2014","unstructured":"Kumari, S. et al. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proc. Natl Acad. Sci. USA 111, 403\u2013408 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR110","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2016-09-737536","volume":"129","author":"L Jahn","year":"2017","unstructured":"Jahn, L. et al. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. Blood 129, 1284\u20131295 (2017).","journal-title":"Blood"},{"key":"857_CR111","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41587-021-01089-x","volume":"40","author":"M Ali","year":"2022","unstructured":"Ali, M. et al. T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. Nat. Biotechnol. 40, 488\u2013498 (2022).","journal-title":"Nat. Biotechnol."},{"key":"857_CR112","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439\u20131453.e19 (2018).","journal-title":"Cell"},{"key":"857_CR113","doi-asserted-by":"publisher","first-page":"7358","DOI":"10.4049\/jimmunol.180.11.7358","volume":"180","author":"Y Kikushige","year":"2008","unstructured":"Kikushige, Y. et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte\/macrophage progenitor stages to maintain cell survival. J. Immunol. 180, 7358\u20137367 (2008).","journal-title":"J. Immunol."},{"key":"857_CR114","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1182\/blood.V88.5.1594.1594","volume":"88","author":"J Olweus","year":"1996","unstructured":"Olweus, J., Terstappen, L. W. M. M., Thompson, P. A. & Lund-Johansen, F. Expression and function of receptors for stem cell factor and erythropoietin during lineage commitment of human hematopoietic progenitor cells. Blood 88, 1594\u20131607 (1996).","journal-title":"Blood"},{"key":"857_CR115","doi-asserted-by":"publisher","first-page":"12551","DOI":"10.1073\/pnas.94.23.12551","volume":"94","author":"J Olweus","year":"1997","unstructured":"Olweus, J. et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc. Natl Acad. Sci. USA 94, 12551\u201312556 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR116","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi1145","volume":"15","author":"N Wellhausen","year":"2023","unstructured":"Wellhausen, N. et al. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci. Transl. Med. 15, eadi1145 (2023).","journal-title":"Sci. Transl. Med."},{"key":"857_CR117","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231235","volume":"220","author":"R Marone","year":"2023","unstructured":"Marone, R. et al. Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy. J. Exp. Med. 220, e20231235 (2023).","journal-title":"J. Exp. Med."},{"key":"857_CR118","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","volume":"621","author":"G Casirati","year":"2023","unstructured":"Casirati, G. et al. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. Nature 621, 404\u2013414 (2023).","journal-title":"Nature"},{"key":"857_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4600","volume":"5","author":"DP Granados","year":"2014","unstructured":"Granados, D. P. et al. Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides. Nat. Commun. 5, 3600 (2014).","journal-title":"Nat. Commun."},{"key":"857_CR120","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/leu.2016.22","volume":"30","author":"DP Granados","year":"2016","unstructured":"Granados, D. P. et al. Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers. Leukemia 30, 1344\u20131354 (2016).","journal-title":"Leukemia"},{"key":"857_CR121","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3389\/fimmu.2018.01819","volume":"9","author":"NA Bykova","year":"2018","unstructured":"Bykova, N. A., Malko, D. B. & Efimov, G. A. In silico analysis of the minor histocompatibility antigen landscape based on the 1000 Genomes Project. Front. Immunol. 9, 1819 (2018).","journal-title":"Front. Immunol."},{"key":"857_CR122","doi-asserted-by":"publisher","first-page":"8639","DOI":"10.1073\/pnas.96.15.8639","volume":"96","author":"D Bonnet","year":"1999","unstructured":"Bonnet, D., Warren, E. H., Greenberg, P. D., Dick, J. E. & Riddell, S. R. CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc. Natl Acad. Sci. USA 96, 8639\u20138644 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR123","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1126\/science.279.5353.1054","volume":"279","author":"JM den Haan","year":"1998","unstructured":"den Haan, J. M. et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279, 1054\u20131057 (1998).","journal-title":"Science"},{"key":"857_CR124","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.bbmt.2012.09.008","volume":"19","author":"W Hobo","year":"2013","unstructured":"Hobo, W. et al. Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol. Blood Marrow Transpl. 19, 274\u2013282 (2013).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"857_CR125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155165","volume":"11","author":"MJ Pont","year":"2016","unstructured":"Pont, M. J. et al. Microarray gene expression analysis to evaluate cell type specific expression of targets relevant for immunotherapy of hematological malignancies. PLoS One 11, e0155165 (2016).","journal-title":"PLoS One"},{"key":"857_CR126","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3389\/fimmu.2020.01804","volume":"11","author":"P van Balen","year":"2020","unstructured":"van Balen, P. et al. HA-1H T-cell receptor gene transfer to redirect virus-specific T cells for treatment of hematological malignancies after allogeneic stem cell transplantation: a phase 1 clinical study. Front. Immunol. 11, 1804 (2020).","journal-title":"Front. Immunol."},{"key":"857_CR127","doi-asserted-by":"crossref","unstructured":"Al Malki, M. M. et al. 924 TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT with reduced intensity conditioning (RIC): preliminary results from the phase 1 alloha. ASH 2024 Proc. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper201526.html (2024).","DOI":"10.1182\/blood-2024-201526"},{"key":"857_CR128","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood.2024024105","volume":"144","author":"EF Krakow","year":"2024","unstructured":"Krakow, E. F. et al. HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation. Blood 144, 1069\u20131082 (2024).","journal-title":"Blood"},{"key":"857_CR129","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1182\/blood-2017-07-791608","volume":"131","author":"RG Dossa","year":"2018","unstructured":"Dossa, R. G. et al. Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse. Blood 131, 108\u2013120 (2018).","journal-title":"Blood"},{"key":"857_CR130","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/bmt.2017.118","volume":"52","author":"LE Franssen","year":"2017","unstructured":"Franssen, L. E. et al. A phase I\/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma. Bone Marrow Transpl. 52, 1378\u20131383 (2017).","journal-title":"Bone Marrow Transpl."},{"key":"857_CR131","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/bmt.2016.250","volume":"52","author":"R Oostvogels","year":"2017","unstructured":"Oostvogels, R. et al. Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients. Bone Marrow Transpl. 52, 228\u2013237 (2017).","journal-title":"Bone Marrow Transpl."},{"key":"857_CR132","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1182\/blood.2023022343","volume":"143","author":"KJ Fuchs","year":"2024","unstructured":"Fuchs, K. J. et al. Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens. Blood 143, 1856\u20131872 (2024).","journal-title":"Blood"},{"key":"857_CR133","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-18-1494","volume":"9","author":"MR Parkhurst","year":"2019","unstructured":"Parkhurst, M. R. et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov. 9, 1022\u20131035 (2019).","journal-title":"Cancer Discov."},{"key":"857_CR134","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy, S. P. et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature 615, 687\u2013696 (2023).","journal-title":"Nature"},{"key":"857_CR135","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner, R. et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med. 386, 2112\u20132119 (2022).","journal-title":"N. Engl. J. Med."},{"key":"857_CR136","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","volume":"10","author":"SP Kim","year":"2022","unstructured":"Kim, S. P. et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. Cancer Immunol. Res. 10, 932\u2013946 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"857_CR137","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"857_CR138","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld, J. et al. Classification and personalized prognosis in myeloproliferative neoplasms. N. Engl. J. Med. 379, 1416\u20131430 (2018).","journal-title":"N. Engl. J. Med."},{"key":"857_CR139","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209\u20132221 (2016).","journal-title":"N. Engl. J. Med."},{"key":"857_CR140","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1182\/blood.2023023727","volume":"144","author":"E Bernard","year":"2024","unstructured":"Bernard, E. et al. Molecular taxonomy of myelodysplastic syndromes and its clinical implications. Blood 144, 1617\u20131632 (2024).","journal-title":"Blood"},{"key":"857_CR141","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature10755","volume":"482","author":"H Matsushita","year":"2012","unstructured":"Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400\u2013404 (2012).","journal-title":"Nature"},{"key":"857_CR142","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1038\/s41588-019-0532-6","volume":"51","author":"J Van den Eynden","year":"2019","unstructured":"Van den Eynden, J., Jimenez-Sanchez, A., Miller, M. L. & Larsson, E. Lack of detectable neoantigen depletion signals in the untreated cancer genome. Nat. Genet. 51, 1741\u20131748 (2019).","journal-title":"Nat. Genet."},{"key":"857_CR143","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00262-021-03028-w","volume":"71","author":"N Kherreh","year":"2022","unstructured":"Kherreh, N., Cleary, S. & Seoighe, C. No evidence that HLA genotype influences the driver mutations that occur in cancer patients. Cancer Immunol. Immunother. 71, 819\u2013827 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"857_CR144","doi-asserted-by":"crossref","unstructured":"Walkowiak, B., MacGregor, H. A. J. & Blundell, J. R. No evidence of immunosurveillance in mutation-hotspot driven clonal haematopoiesis. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2024.09.27.615394v1 (2024).","DOI":"10.1101\/2024.09.27.615394"},{"key":"857_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13404","volume":"7","author":"M Bassani-Sternberg","year":"2016","unstructured":"Bassani-Sternberg, M. et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat. Commun. 7, 13404 (2016).","journal-title":"Nat. Commun."},{"key":"857_CR146","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0636-8","volume":"11","author":"MW Loffler","year":"2019","unstructured":"Loffler, M. W. et al. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Med. 11, 28 (2019).","journal-title":"Genome Med."},{"key":"857_CR147","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"857_CR148","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"857_CR149","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ccr.2005.01.027","volume":"7","author":"CG Drake","year":"2005","unstructured":"Drake, C. G. et al. Androgen ablation mitigates tolerance to a prostate\/prostate cancer-restricted antigen. Cancer Cell 7, 239\u2013249 (2005).","journal-title":"Cancer Cell"},{"key":"857_CR150","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nature03954","volume":"437","author":"G Willimsky","year":"2005","unstructured":"Willimsky, G. & Blankenstein, T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437, 141\u2013146 (2005).","journal-title":"Nature"},{"key":"857_CR151","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","volume":"45","author":"A Schietinger","year":"2016","unstructured":"Schietinger, A. et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45, 389\u2013401 (2016).","journal-title":"Immunity"},{"key":"857_CR152","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"857_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-08871-1","volume":"10","author":"M Noviello","year":"2019","unstructured":"Noviello, M. et al. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat. Commun. 10, 1\u201315 (2019).","journal-title":"Nat. Commun."},{"key":"857_CR154","doi-asserted-by":"publisher","first-page":"13039","DOI":"10.3390\/ijms252313039","volume":"25","author":"YJ Kim","year":"2024","unstructured":"Kim, Y. J. et al. Characterization of the bone marrow lymphoid microenvironment and discovery of prognostic immune-related factors in acute myeloid leukemia. Int. J. Mol. Sci. 25, 13039 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"857_CR155","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1002\/eji.1830261119","volume":"26","author":"B Bogen","year":"1996","unstructured":"Bogen, B. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol. 26, 2671\u20132679 (1996).","journal-title":"Eur. J. Immunol."},{"key":"857_CR156","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1073\/pnas.95.3.1178","volume":"95","author":"K Staveley-O\u2019Carroll","year":"1998","unstructured":"Staveley-O\u2019Carroll, K. et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl Acad. Sci. USA 95, 1178\u20131183 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR157","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1172\/JCI97482","volume":"129","author":"DI van der Lee","year":"2019","unstructured":"van der Lee, D. I. et al. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. J. Clin. Invest. 129, 774\u2013785 (2019).","journal-title":"J. Clin. Invest."},{"key":"857_CR158","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1172\/JCI137723","volume":"130","author":"MA Biernacki","year":"2020","unstructured":"Biernacki, M. A. et al. CBFB\u2013MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia. J. Clin. Invest. 130, 5127\u20135141 (2020).","journal-title":"J. Clin. Invest."},{"key":"857_CR159","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/s43018-023-00642-8","volume":"4","author":"E Giannakopoulou","year":"2023","unstructured":"Giannakopoulou, E. et al. A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo. Nat. Cancer 4, 1474\u20131490 (2023).","journal-title":"Nat. Cancer"},{"key":"857_CR160","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007490","volume":"11","author":"MA Biernacki","year":"2023","unstructured":"Biernacki, M. A. et al. Discovery of U2AF1 neoantigens in myeloid neoplasms. J. Immunother. Cancer 11, e007490 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"857_CR161","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1182\/blood.2023021979","volume":"143","author":"WK Leung","year":"2024","unstructured":"Leung, W. K. et al. Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood 143, 1726\u20131737 (2024).","journal-title":"Blood"},{"key":"857_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24562-2","volume":"12","author":"AS Bear","year":"2021","unstructured":"Bear, A. S. et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nat. Commun. 12, 4365 (2021).","journal-title":"Nat. Commun."},{"key":"857_CR163","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00018-017-2628-4","volume":"75","author":"CM Laumont","year":"2018","unstructured":"Laumont, C. M. & Perreault, C. Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy. Cell Mol. Life Sci. 75, 607\u2013621 (2018).","journal-title":"Cell Mol. Life Sci."},{"key":"857_CR164","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2326-6066.CIR-19-0886","volume":"8","author":"F Erhard","year":"2020","unstructured":"Erhard, F., Dolken, L., Schilling, B. & Schlosser, A. Identification of the cryptic HLA-I immunopeptidome. Cancer Immunol. Res. 8, 1018\u20131026 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"857_CR165","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2221116120","volume":"120","author":"Y Pan","year":"2023","unstructured":"Pan, Y. et al. IRIS: discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing. Proc. Natl Acad. Sci. USA 120, e2221116120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR166","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm6359","volume":"8","author":"A Merlotti","year":"2023","unstructured":"Merlotti, A. et al. Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer. Sci. Immunol. 8, eabm6359 (2023).","journal-title":"Sci. Immunol."},{"key":"857_CR167","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64\u201369 (2011).","journal-title":"Nature"},{"key":"857_CR168","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","volume":"17","author":"SC Bonnal","year":"2020","unstructured":"Bonnal, S. C., Lopez-Oreja, I. & Valcarcel, J. Roles and mechanisms of alternative splicing in cancer\u2014implications for care. Nat. Rev. Clin. Oncol. 17, 457\u2013474 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"857_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.03.047","author":"WJ Kim","year":"2025","unstructured":"Kim, W. J. et al. Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias. Cell https:\/\/doi.org\/10.1016\/j.cell.2025.03.047 (2025).","journal-title":"Cell"},{"key":"857_CR170","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-024-08552-0","volume":"639","author":"DW Kwok","year":"2025","unstructured":"Kwok, D. W. et al. Tumour-wide RNA splicing aberrations generate actionable public neoantigens. Nature 639, 463\u2013473 (2025).","journal-title":"Nature"},{"key":"857_CR171","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1158\/1078-0432.CCR-22-3298","volume":"29","author":"M Lozano-Rabella","year":"2023","unstructured":"Lozano-Rabella, M. et al. Exploring the immunogenicity of noncanonical HLA-I tumor ligands identified through proteogenomics. Clin. Cancer Res. 29, 2250\u20132265 (2023).","journal-title":"Clin. Cancer Res."},{"key":"857_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19464-8","volume":"11","author":"SK Saini","year":"2020","unstructured":"Saini, S. K. et al. Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers. Nat. Commun. 11, 5660 (2020).","journal-title":"Nat. Commun."},{"key":"857_CR173","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41586-020-03054-1","volume":"590","author":"O Bartok","year":"2021","unstructured":"Bartok, O. et al. Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature 590, 332\u2013337 (2021).","journal-title":"Nature"},{"key":"857_CR174","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41586-022-04499-2","volume":"603","author":"A Pataskar","year":"2022","unstructured":"Pataskar, A. et al. Tryptophan depletion results in tryptophan-to-phenylalanine substitutants. Nature 603, 721\u2013727 (2022).","journal-title":"Nature"},{"key":"857_CR175","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.immuni.2024.12.004","volume":"58","author":"J Champagne","year":"2025","unstructured":"Champagne, J. et al. Adoptive T cell therapy targeting a broadly shared, inducible product of aberrant mRNA translation. Immunity 58, 247\u2013262.e9 (2025).","journal-title":"Immunity"},{"key":"857_CR176","doi-asserted-by":"publisher","unstructured":"Weller, C. et al. Translation dysregulation in cancer as a source for targetable antigens. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2025.03.003 (2025).","DOI":"10.1016\/j.ccell.2025.03.003"},{"key":"857_CR177","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41587-022-01464-2","volume":"41","author":"A Kacen","year":"2023","unstructured":"Kacen, A. et al. Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors. Nat. Biotechnol. 41, 239\u2013251 (2023).","journal-title":"Nat. Biotechnol."},{"key":"857_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39425-1","volume":"14","author":"Y Patskovsky","year":"2023","unstructured":"Patskovsky, Y. et al. Molecular mechanism of phosphopeptide neoantigen immunogenicity. Nat. Commun. 14, 3763 (2023).","journal-title":"Nat. Commun."},{"key":"857_CR179","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488\u20132498 (2014).","journal-title":"N. Engl. J. Med."},{"key":"857_CR180","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477\u20132487 (2014).","journal-title":"N. Engl. J. Med."},{"key":"857_CR181","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1182\/blood.2023022222","volume":"142","author":"LD Weeks","year":"2023","unstructured":"Weeks, L. D. & Ebert, B. L. Causes and consequences of clonal hematopoiesis. Blood 142, 2235\u20132246 (2023).","journal-title":"Blood"},{"key":"857_CR182","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","volume":"24","author":"P Desai","year":"2018","unstructured":"Desai, P. et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat. Med. 24, 1015\u20131023 (2018).","journal-title":"Nat. Med."},{"key":"857_CR183","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1182\/blood.2020010483","volume":"138","author":"T Tanaka","year":"2021","unstructured":"Tanaka, T. et al. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood 138, 1733\u20131739 (2021).","journal-title":"Blood"},{"key":"857_CR184","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41586-018-0497-0","volume":"561","author":"H Lee-Six","year":"2018","unstructured":"Lee-Six, H. et al. Population dynamics of normal human blood inferred from somatic mutations. Nature 561, 473\u2013478 (2018).","journal-title":"Nature"},{"key":"857_CR185","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41591-020-01182-9","volume":"27","author":"R Sender","year":"2021","unstructured":"Sender, R. & Milo, R. The distribution of cellular turnover in the human body. Nat. Med. 27, 45\u201348 (2021).","journal-title":"Nat. Med."},{"key":"857_CR186","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.celrep.2018.11.014","volume":"25","author":"FG Osorio","year":"2018","unstructured":"Osorio, F. G. et al. Somatic mutations reveal lineage relationships and age-related mutagenesis in human hematopoiesis. Cell Rep. 25, 2308\u20132316.e4 (2018).","journal-title":"Cell Rep."},{"key":"857_CR187","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","volume":"150","author":"JS Welch","year":"2012","unstructured":"Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264\u2013278 (2012).","journal-title":"Cell"},{"key":"857_CR188","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","volume":"587","author":"LA Miles","year":"2020","unstructured":"Miles, L. A. et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature 587, 477\u2013482 (2020).","journal-title":"Nature"},{"key":"857_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19119-8","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita, K. et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat. Commun. 11, 5327 (2020).","journal-title":"Nat. Commun."},{"key":"857_CR190","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/leu.2010.159","volume":"24","author":"I Sloma","year":"2010","unstructured":"Sloma, I., Jiang, X., Eaves, A. C. & Eaves, C. J. Insights into the stem cells of chronic myeloid leukemia. Leukemia 24, 1823\u20131833 (2010).","journal-title":"Leukemia"},{"key":"857_CR191","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","volume":"19","author":"N Goardon","year":"2011","unstructured":"Goardon, N. et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19, 138\u2013152 (2011).","journal-title":"Cancer Cell"},{"key":"857_CR192","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1182\/blood-2007-10-118331","volume":"112","author":"DC Taussig","year":"2008","unstructured":"Taussig, D. C. et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112, 568\u2013575 (2008).","journal-title":"Blood"},{"key":"857_CR193","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.stemcr.2020.05.013","volume":"15","author":"HJ Uckelmann","year":"2020","unstructured":"Uckelmann, H. J. & Armstrong, S. A. Chromatin complexes maintain self-renewal of myeloid progenitors in AML: opportunities for therapeutic intervention. Stem Cell Rep. 15, 6\u201312 (2020).","journal-title":"Stem Cell Rep."},{"key":"857_CR194","doi-asserted-by":"publisher","first-page":"eabf6202","DOI":"10.1126\/science.abf6202","volume":"373","author":"E Wagenblast","year":"2021","unstructured":"Wagenblast, E. et al. Mapping the cellular origin and early evolution of leukemia in Down syndrome. Science 373, eabf6202 (2021).","journal-title":"Science"},{"key":"857_CR195","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1182\/bloodadvances.2019001181","volume":"4","author":"A Ediriwickrema","year":"2020","unstructured":"Ediriwickrema, A. et al. Single-cell mutational profiling enhances the clinical evaluation of AML MRD. Blood Adv. 4, 943\u2013952 (2020).","journal-title":"Blood Adv."},{"key":"857_CR196","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature22993","volume":"547","author":"LI Shlush","year":"2017","unstructured":"Shlush, L. I. et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 547, 104\u2013108 (2017).","journal-title":"Nature"},{"key":"857_CR197","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1056\/NEJMoa0912228","volume":"363","author":"R Tehranchi","year":"2010","unstructured":"Tehranchi, R. et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N. Engl. J. Med. 363, 1025\u20131037 (2010).","journal-title":"N. Engl. J. Med."},{"key":"857_CR198","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie, D., Helgason, G. V. & Copland, M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat. Rev. Cancer 20, 158\u2013173 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"857_CR199","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1172\/JCI1681","volume":"101","author":"N Uchida","year":"1998","unstructured":"Uchida, N. et al. High doses of purified stem cells cause early hematopoietic recovery in syngeneic and allogeneic hosts. J. Clin. Invest. 101, 961\u2013966 (1998).","journal-title":"J. Clin. Invest."},{"key":"857_CR200","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1182\/blood.2023022851","volume":"143","author":"M Dimitriou","year":"2024","unstructured":"Dimitriou, M. et al. Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation. Blood 143, 953\u2013966 (2024).","journal-title":"Blood"},{"key":"857_CR201","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.2415","volume":"17","author":"K Eppert","year":"2011","unstructured":"Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17, 1086\u20131093 (2011).","journal-title":"Nat. Med."},{"key":"857_CR202","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng, S. W. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433\u2013437 (2016).","journal-title":"Nature"},{"key":"857_CR203","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/oxfordjournals.annonc.a059321","volume":"6","author":"J Brieger","year":"1995","unstructured":"Brieger, J. et al. The Wilms\u2019 tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR. Ann. Oncol. 6, 811\u2013816 (1995).","journal-title":"Ann. Oncol."},{"key":"857_CR204","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/joim.13283","volume":"289","author":"PS Woll","year":"2021","unstructured":"Woll, P. S. & Jacobsen, S. E. W. Stem cell concepts in myelodysplastic syndromes: lessons and challenges. J. Intern. Med. 289, 650\u2013661 (2021).","journal-title":"J. Intern. Med."},{"key":"857_CR205","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/ijc.29583","volume":"137","author":"V Schneider","year":"2015","unstructured":"Schneider, V. et al. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. Int. J. Cancer 137, 2083\u20132092 (2015).","journal-title":"Int. J. Cancer"},{"key":"857_CR206","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","volume":"14","author":"CT Jordan","year":"2000","unstructured":"Jordan, C. T. et al. The interleukin-3 receptor \u03b1 chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777\u20131784 (2000).","journal-title":"Leukemia"},{"key":"857_CR207","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2643-3230.BCD-23-0020","volume":"4","author":"A Nelde","year":"2023","unstructured":"Nelde, A. et al. Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells. Blood Cancer Discov. 4, 468\u2013489 (2023).","journal-title":"Blood Cancer Discov."},{"key":"857_CR208","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/ni1080","volume":"5","author":"KJ Hope","year":"2004","unstructured":"Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5, 738\u2013743 (2004).","journal-title":"Nat. Immunol."},{"key":"857_CR209","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","volume":"118","author":"S Chu","year":"2011","unstructured":"Chu, S. et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118, 5565\u20135572 (2011).","journal-title":"Blood"},{"key":"857_CR210","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nbt.1607","volume":"28","author":"Y Saito","year":"2010","unstructured":"Saito, Y. et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 28, 275\u2013280 (2010).","journal-title":"Nat. Biotechnol."},{"key":"857_CR211","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.immuni.2018.02.001","volume":"48","author":"J Agudo","year":"2018","unstructured":"Agudo, J. et al. Quiescent tissue stem cells evade immune surveillance. Immunity 48, 271\u2013285.e5 (2018).","journal-title":"Immunity"},{"key":"857_CR212","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1016\/j.cell.2023.07.016","volume":"186","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell 186, 3903\u20133920.e21 (2023).","journal-title":"Cell"},{"key":"857_CR213","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.it.2024.01.009","volume":"45","author":"J Wang","year":"2024","unstructured":"Wang, J., Lu, Q., Chen, X. & Aifantis, I. Targeting MHC-I inhibitory pathways for cancer immunotherapy. Trends Immunol. 45, 177\u2013187 (2024).","journal-title":"Trends Immunol."},{"key":"857_CR214","first-page":"27","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry, A. et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat. Cancer 4, 27\u201342 (2023).","journal-title":"Nat. Cancer"},{"key":"857_CR215","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1158\/2159-8290.CD-21-1146","volume":"12","author":"A Yeaton","year":"2022","unstructured":"Yeaton, A. et al. The impact of inflammation-induced tumor plasticity during myeloid transformation. Cancer Discov. 12, 2392\u20132413 (2022).","journal-title":"Cancer Discov."},{"key":"857_CR216","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1182\/blood.2023019961","volume":"143","author":"J Vadakekolathu","year":"2024","unstructured":"Vadakekolathu, J. & Rutella, S. Escape from T-cell-targeting immunotherapies in acute myeloid leukemia. Blood 143, 2689\u20132700 (2024).","journal-title":"Blood"},{"key":"857_CR217","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.ymthe.2018.02.017","volume":"26","author":"HM Bijen","year":"2018","unstructured":"Bijen, H. M. et al. Preclinical strategies to identify off-target toxicity of high-affinity TCRs. Mol. Ther. 26, 1206\u20131214 (2018).","journal-title":"Mol. Ther."},{"key":"857_CR218","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1682381","volume":"9","author":"JP Sanderson","year":"2020","unstructured":"Sanderson, J. P. et al. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. Oncoimmunology 9, 1682381 (2020).","journal-title":"Oncoimmunology"},{"key":"857_CR219","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00713-y","volume":"8","author":"Z Foldvari","year":"2023","unstructured":"Foldvari, Z. et al. A systematic safety pipeline for selection of T-cell receptors to enter clinical use. NPJ Vaccines 8, 126 (2023).","journal-title":"NPJ Vaccines"},{"key":"857_CR220","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.omtm.2023.01.005","volume":"28","author":"RA van Amerongen","year":"2023","unstructured":"van Amerongen, R. A. et al. Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential. Mol. Ther. Methods Clin. Dev. 28, 249\u2013261 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"857_CR221","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1016\/j.immuni.2024.11.009","volume":"57","author":"NS Abdelfattah","year":"2024","unstructured":"Abdelfattah, N. S., Kula, T. & Elledge, S. J. T-switch: a specificity-based engineering platform for developing safe and effective T cell therapeutics. Immunity 57, 2945\u20132958.e5 (2024).","journal-title":"Immunity"},{"key":"857_CR222","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1182\/bloodadvances.2019000194","volume":"3","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer, E. A. et al. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. Blood Adv. 3, 2022\u20132034 (2019).","journal-title":"Blood Adv."},{"key":"857_CR223","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-23-1456","volume":"29","author":"A Kawai","year":"2023","unstructured":"Kawai, A. et al. Safety and efficacy of NY-ESO-1 antigen-specific T-cell receptor gene-transduced T lymphocytes in patients with synovial sarcoma: a phase I\/II clinical trial. Clin. Cancer Res. 29, 5069\u20135078 (2023).","journal-title":"Clin. Cancer Res."},{"key":"857_CR224","doi-asserted-by":"publisher","first-page":"100977","DOI":"10.1016\/j.esmoop.2023.100977","volume":"8","author":"J Arnon","year":"2023","unstructured":"Arnon, J. et al. 11P successful transfer and prolonged persistence of engineered lymphocytes with T-cell receptor targeting NY-ESO-1. ESMO Open. 8, 100977\u2013100977 (2023).","journal-title":"ESMO Open."},{"key":"857_CR225","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3389\/fimmu.2019.02501","volume":"10","author":"AR Karapetyan","year":"2019","unstructured":"Karapetyan, A. R. et al. TCR fingerprinting and off-target peptide identification. Front. Immunol. 10, 2501 (2019).","journal-title":"Front. Immunol."},{"key":"857_CR226","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003811","volume":"10","author":"M Ishihara","year":"2022","unstructured":"Ishihara, M. et al. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. J. Immunother. Cancer 10, e003811 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"857_CR227","doi-asserted-by":"crossref","unstructured":"Ou, Y. et al. Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal potency and high specificity. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2022.10.12.511904v1 (2022).","DOI":"10.1101\/2022.10.12.511904"},{"key":"857_CR228","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 30, 338\u2013341 (2024).","journal-title":"Nat. Med."},{"key":"857_CR229","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1182\/bloodadvances.2024013243","volume":"8","author":"AJ Lamble","year":"2024","unstructured":"Lamble, A. J. et al. Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults. Blood Adv. 8, 3544\u20133548 (2024).","journal-title":"Blood Adv."},{"key":"857_CR230","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton, M. P. et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N. Engl. J. Med. 390, 2047\u20132060 (2024).","journal-title":"N. Engl. J. Med."},{"key":"857_CR231","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27312-6","volume":"12","author":"M Maschan","year":"2021","unstructured":"Maschan, M. et al. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat. Commun. 12, 7200 (2021).","journal-title":"Nat. Commun."},{"key":"857_CR232","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/d41586-024-00809-y","volume":"627","author":"S Mallapaty","year":"2024","unstructured":"Mallapaty, S. Cutting-edge CAR-T cancer therapy is now made in India\u2014at one-tenth the cost. Nature 627, 709\u2013710 (2024).","journal-title":"Nature"},{"key":"857_CR233","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41551-019-0409-0","volume":"3","author":"K Schober","year":"2019","unstructured":"Schober, K. et al. Orthotopic replacement of T-cell receptor \u03b1- and \u03b2-chains with preservation of near-physiological T-cell function. Nat. Biomed. Eng. 3, 974\u2013984 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"857_CR234","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43586-023-00278-z","volume":"4","author":"US Tretbar","year":"2024","unstructured":"Tretbar, U. S. et al. Non-viral vectors for chimeric antigen receptor immunotherapy. Nat. Rev. Methods Prim. 4, 1\u201319 (2024).","journal-title":"Nat. Rev. Methods Prim."},{"key":"857_CR235","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.4049\/jimmunol.1000173","volume":"184","author":"DA Schmid","year":"2010","unstructured":"Schmid, D. A. et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J. Immunol. 184, 4936\u20134946 (2010).","journal-title":"J. Immunol."},{"key":"857_CR236","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92570","volume":"2","author":"M Allard","year":"2017","unstructured":"Allard, M. et al. TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency. JCI Insight 2, e92570 (2017).","journal-title":"JCI Insight"},{"key":"857_CR237","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/ni.2538","volume":"14","author":"CS Guy","year":"2013","unstructured":"Guy, C. S. et al. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat. Immunol. 14, 262\u2013270 (2013).","journal-title":"Nat. Immunol."},{"key":"857_CR238","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood-2011-06-360354","volume":"119","author":"K Nagai","year":"2012","unstructured":"Nagai, K. et al. Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity. Blood 119, 368\u2013376 (2012).","journal-title":"Blood"},{"key":"857_CR239","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1172\/JCI75876","volume":"125","author":"C Arber","year":"2015","unstructured":"Arber, C. et al. Survivin-specific T cell receptor targets tumor but not T cells. J. Clin. Invest. 125, 157\u2013168 (2015).","journal-title":"J. Clin. Invest."},{"key":"857_CR240","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1074-7613(03)00019-0","volume":"18","author":"PD Holler","year":"2003","unstructured":"Holler, P. D. & Kranz, D. M. Quantitative analysis of the contribution of TCR\/pepMHC affinity and CD8 to T cell activation. Immunity 18, 255\u2013264 (2003).","journal-title":"Immunity"},{"key":"857_CR241","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002035","volume":"9","author":"K Davari","year":"2021","unstructured":"Davari, K. et al. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy. J. Immunother. Cancer 9, e002035 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"857_CR242","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).","journal-title":"Science"},{"key":"857_CR243","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535\u2013546 (2009).","journal-title":"Blood"},{"key":"857_CR244","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/1078-0432.CCR-13-3017","volume":"20","author":"T Chodon","year":"2014","unstructured":"Chodon, T. et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin. Cancer Res. 20, 2457\u20132465 (2014).","journal-title":"Clin. Cancer Res."},{"key":"857_CR245","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1158\/2159-8290.CD-22-0199","volume":"13","author":"AO Khan","year":"2023","unstructured":"Khan, A. O. et al. Human bone marrow organoids for disease modeling, discovery, and validation of therapeutic targets in hematologic malignancies. Cancer Discov. 13, 364\u2013385 (2023).","journal-title":"Cancer Discov."},{"key":"857_CR246","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","volume":"40","author":"MB Leick","year":"2022","unstructured":"Leick, M. B. et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell 40, 494\u2013508.e5 (2022).","journal-title":"Cancer Cell"},{"key":"857_CR247","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1515\/hsz-2023-0341","volume":"405","author":"A Carr","year":"2024","unstructured":"Carr, A. et al. Advances in preclinical TCR characterization: leveraging cell avidity to identify functional TCRs. Biol. Chem. 405, 517\u2013529 (2024).","journal-title":"Biol. Chem."},{"key":"857_CR248","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2024-011351","volume":"13","author":"L Rosenberger","year":"2025","unstructured":"Rosenberger, L. et al. Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire. J. Immunother. Cancer 13, 1\u201313 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"857_CR249","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"857_CR250","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101241","volume":"68","author":"AK Arunachalam","year":"2024","unstructured":"Arunachalam, A. K., Gregoire, C., Coutinho de Oliveira, B. & Melenhorst, J. J. Advancing CAR T-cell therapies: preclinical insights and clinical translation for hematological malignancies. Blood Rev. 68, 101241 (2024).","journal-title":"Blood Rev."},{"key":"857_CR251","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1182\/blood-2014-02-556340","volume":"123","author":"M Wunderlich","year":"2014","unstructured":"Wunderlich, M. et al. OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues. Blood 123, e134\u2013e144 (2014).","journal-title":"Blood"},{"key":"857_CR252","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nm.2700","volume":"18","author":"E Provasi","year":"2012","unstructured":"Provasi, E. et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18, 807\u2013815 (2012).","journal-title":"Nat. Med."},{"key":"857_CR253","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","volume":"186","author":"CA Tsuchida","year":"2023","unstructured":"Tsuchida, C. A. et al. Mitigation of chromosome loss in clinical CRISPR\u2013Cas9-engineered T cells. Cell 186, 4567\u20134582.e20 (2023).","journal-title":"Cell"},{"key":"857_CR254","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","volume":"41","author":"A Gottschlich","year":"2023","unstructured":"Gottschlich, A. et al. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat. Biotechnol. 41, 1618\u20131632 (2023).","journal-title":"Nat. Biotechnol."},{"key":"857_CR255","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","volume":"32","author":"F Perna","year":"2017","unstructured":"Perna, F. et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 32, 506\u2013519.e5 (2017).","journal-title":"Cancer Cell"},{"key":"857_CR256","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41586-019-1104-8","volume":"569","author":"AN Tikhonova","year":"2019","unstructured":"Tikhonova, A. N. et al. The bone marrow microenvironment at single-cell resolution. Nature 569, 222\u2013228 (2019).","journal-title":"Nature"},{"key":"857_CR257","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","volume":"41","author":"S Haubner","year":"2023","unstructured":"Haubner, S. et al. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell 41, 1871\u20131891.e6 (2023).","journal-title":"Cancer Cell"},{"key":"857_CR258","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1182\/blood.2023021054","volume":"143","author":"T Dao","year":"2024","unstructured":"Dao, T. et al. A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML. Blood 143, 507\u2013521 (2024).","journal-title":"Blood"},{"key":"857_CR259","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41568-024-00723-5","volume":"24","author":"N Wellhausen","year":"2024","unstructured":"Wellhausen, N., Baek, J., Gill, S. I. & June, C. H. Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance. Nat. Rev. Cancer 24, 614\u2013628 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"857_CR260","doi-asserted-by":"publisher","unstructured":"Pogorelyy, M. V. et al. TIRTL-seq: deep, quantitative, and affordable paired TCR repertoire sequencing. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.09.16.613345 (2024).","DOI":"10.1101\/2024.09.16.613345"},{"key":"857_CR261","doi-asserted-by":"publisher","unstructured":"Messemaker, M. et al. A functionally validated TCR-pMHC database for TCR specificity model development. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.04.28.651095 (2025).","DOI":"10.1101\/2025.04.28.651095"},{"key":"857_CR262","doi-asserted-by":"publisher","first-page":"D406","DOI":"10.1093\/nar\/gkx971","volume":"46","author":"J Leem","year":"2018","unstructured":"Leem, J., de Oliveira, S. H. P., Krawczyk, K. & Deane, C. M. STCRDab: the structural T-cell receptor database. Nucleic Acids Res. 46, D406\u2013D412 (2018).","journal-title":"Nucleic Acids Res."},{"key":"857_CR263","unstructured":"Nobel Prize Organization. Nobel Prize in Chemistry 2024 [press release]; https:\/\/www.nobelprize.org\/prizes\/chemistry\/2024\/press-release\/ (2024)."},{"key":"857_CR264","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3324\/haematol.2010.025916","volume":"96","author":"MM van Loenen","year":"2011","unstructured":"van Loenen, M. M. et al. Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies. Haematologica 96, 477\u2013481 (2011).","journal-title":"Haematologica"},{"key":"857_CR265","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3324\/haematol.2013.093690","volume":"99","author":"MM van Loenen","year":"2014","unstructured":"van Loenen, M. M. et al. A good manufacturing practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells. Haematologica 99, 759\u2013768 (2014).","journal-title":"Haematologica"},{"key":"857_CR266","doi-asserted-by":"publisher","first-page":"TPS2678","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2678","volume":"42","author":"MM Al Malki","year":"2024","unstructured":"Al Malki, M. M. et al. A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. J. Clin. Oncol. 42, TPS2678 (2024).","journal-title":"J. Clin. Oncol."},{"key":"857_CR267","first-page":"A173","volume":"9","author":"G Bajwa","year":"2021","unstructured":"Bajwa, G. et al. 163 Improved anti-tumor activity of next-generation TCR-engineered T cells through CD8 co-expression. J. Immunother. Cancer 9, A173 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"857_CR268","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3324\/haematol.2009.006486","volume":"95","author":"S-A Xue","year":"2010","unstructured":"Xue, S.-A. et al. Development of a Wilms\u2019 tumor antigen-specific T-cell receptor for clinical trials: engineered patient\u2019s T cells can eliminate autologous leukemia blasts in NOD\/SCID mice. Haematologica 95, 126\u2013134 (2010).","journal-title":"Haematologica"},{"key":"857_CR269","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/blood.V95.1.286","volume":"95","author":"H Ohminami","year":"2000","unstructured":"Ohminami, H., Yasukawa, M. & Fujita, S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95, 286\u2013293 (2000).","journal-title":"Blood"},{"key":"857_CR270","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2011-02-337089","volume":"118","author":"T Ochi","year":"2011","unstructured":"Ochi, T. et al. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood 118, 1495\u20131503 (2011).","journal-title":"Blood"},{"key":"857_CR271","doi-asserted-by":"crossref","first-page":"A788","DOI":"10.1136\/jitc-2023-008668","volume":"12","author":"M Wermke","year":"2024","unstructured":"Wermke, M. et al. 687 ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients. J. Immunother. Cancer 12, A788 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"857_CR272","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02408016 (2021)."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41568-025-00857-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-025-00857-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-025-00857-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T13:02:58Z","timestamp":1763989378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41568-025-00857-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":272,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["857"],"URL":"https:\/\/doi.org\/10.1038\/s41568-025-00857-0","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"3 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.O. is an inventor on several patents and patent applications protecting TCR sequences owned by Oslo University Hospital\/University of Oslo; is on the scientific advisory board of Asgard Therapeutics; and is cofounder of T-Rx therapeutics. Z.F., M.S.B., A.T. and S.E.W.J. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}